Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 450

1.

Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay.

Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, He X, Palazzo JP, Olopade OI, Szabo A, Perou CM, Bernard PS.

Breast Cancer Res. 2006;8(2):R23. Epub 2006 Apr 20.

2.

Identification of endogenous reference genes for qRT-PCR analysis in normal matched breast tumor tissues.

Gur-Dedeoglu B, Konu O, Bozkurt B, Ergul G, Seckin S, Yulug IG.

Oncol Res. 2009;17(8):353-65.

PMID:
19544972
3.

Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.

Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3249-56.

4.

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, Flury R, Dieterich H, Spyratos F, Eppenberger U, Eppenberger-Castori S.

Breast Cancer Res. 2007;9(3):R33.

5.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

6.

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.

Breast Cancer Res Treat. 2009 Jan;113(2):275-83. doi: 10.1007/s10549-008-9939-y. Epub 2008 Mar 4.

PMID:
18311582
7.

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M.

J Natl Cancer Inst. 2006 Feb 15;98(4):262-72.

PMID:
16478745
8.

Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.

Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U, Eppenberger-Castori S.

J Clin Oncol. 2006 Sep 10;24(26):4245-53.

PMID:
16963728
9.

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.

Breast Cancer Res. 2008;10(5):R74. doi: 10.1186/bcr2139. Epub 2008 Sep 4.

10.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
11.

Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

Ann Surg Oncol. 2007 Oct;14(10):2994-3003. Epub 2007 Jul 24.

PMID:
17647064
12.

Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.

Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C.

Clin Cancer Res. 2008 Aug 15;14(16):5158-65. doi: 10.1158/1078-0432.CCR-07-4756.

13.

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.

Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY.

Breast Cancer Res Treat. 2006 Feb;95(3):243-55. Epub 2005 Oct 27.

14.

Gene expression signatures in breast cancer distinguish phenotype characteristics, histologic subtypes, and tumor invasiveness.

Pedraza V, Gomez-Capilla JA, Escaramis G, Gomez C, Torné P, Rivera JM, Gil A, Araque P, Olea N, Estivill X, Fárez-Vidal ME.

Cancer. 2010 Jan 15;116(2):486-96. doi: 10.1002/cncr.24805.

15.
16.

Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer.

Bektas N, Haaf At, Veeck J, Wild PJ, Lüscher-Firzlaff J, Hartmann A, Knüchel R, Dahl E.

BMC Cancer. 2008 Feb 6;8:42. doi: 10.1186/1471-2407-8-42.

17.

A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.

18.

Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer.

Stein T, Price KN, Morris JS, Heath VJ, Ferrier RK, Bell AK, Pringle MA, Villadsen R, Petersen OW, Sauter G, Bryson G, Mallon EA, Gusterson BA.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6872-9.

19.

Predicting features of breast cancer with gene expression patterns.

Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL.

Breast Cancer Res Treat. 2008 Mar;108(2):191-201. doi: 10.1007/s10549-007-9596-6. Epub 2007 May 22.

PMID:
18297396

Supplemental Content

Support Center